Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on BAY 43-9006
EMERYVILLE, Calif., — Mar. 21, 2005
Contact:
Julie Wood
510-597-6505
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a conference call on Monday, March 21, 2005 at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time) to provide an update on sorafenib, formerly known as BAY 43-9006.
Interested parties may access the live presentation at:
http://phx.corporate-ir.net/playerlink.zhtml?c=112065&s=wm&e=1040534
or by dialing 617-614-4911 and using the passcode 43348225. A replay of the presentation will be available on the Onyx website or by dialing 617-801-6888 and using the passcode 98957198 approximately one hour after the teleconference concludes. The replay will be available through April 21, 2005.
Onyx Pharmaceuticals is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborators, the company is developing small molecule drugs, including sorafenib (BAY 43-9006) with Bayer Pharmaceuticals Corporation. For more information about Onyx’s pipeline and activities, visit the company’s website at
www.onyx-pharm.com.
Back to 2005 Press Releases
